Stock Price Quote

SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

NSE : SPARCBSE : 532872ISIN CODE : INE232I01014Industry : Business SupportHouse : Sun Pharma
BSE351.20-18.45 (-4.99 %)
PREV CLOSE ( ) 369.65
OPEN PRICE ( ) 351.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6704
TODAY'S LOW / HIGH ( )351.20 351.20
52 WK LOW / HIGH ( )178.1 474
NSE350.05-18.4 (-4.99 %)
PREV CLOSE( ) 368.45
OPEN PRICE ( ) 350.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 350.05 (152557)
VOLUME 83387
TODAY'S LOW / HIGH( ) 350.05 350.05
52 WK LOW / HIGH ( )178.8 472.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-03 2006
Management Info
Dilip S Shanghvi - Chairman - Managing Director
Registered Office

Address Plot No.5 & 6/1, Savli G. I. D. C. Estate,Savli - Vadodara Highway,Manjusar ,
Vadodara,
Gujarat-391775

Phone 0265- 2330815

Email secretarial@sparcmail.com

Website www.sparc.life

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

10Apr Sun Pharma Advanced Research Company i
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
10Apr Sun Pharma Advanced Research Company i
Sun Pharma Advanced Research Company has confirmed that activities in re..
07Mar Sun Pharma Advanced Research Company i
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..
04Jan Sun Pharma Advanced Research Company i
Sun Pharma Advanced Research Company has confirmed that the Company is i..
06Nov Sun Pharma Advanced Research Company i
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-996.5-2225.8
Gross Profit -996.5 -2225.8
Operating Profit -962.3-2031.8
Net Sales 138.62387.8

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Just Dial (BSE)
peergroup  1009.95 (12.97%)
M.Cap ( in Cr)8588.39
Dynavision (BSE)
peergroup  371.55 (9.99%)
M.Cap ( in Cr)142.68
Techknowgreen Solutn (BSE)
peergroup  233.25 (11.07%)
M.Cap ( in Cr)172.20
Swadeshi Polytex (BSE)
peergroup  221.45 (4.98%)
M.Cap ( in Cr)863.66
Jaykay Enterprises (BSE)
peergroup  132.60 (4.99%)
M.Cap ( in Cr)775.15

Shareholding Pattern

PROMOTERS 65.67%
NON-INSTITUTION 30.42%
MUTUAL FUNDS/UTI 0.25%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Sun Pharma Advanced Research Company Ltd.

Sun Pharma Advanced Research Company Ltd. was incorporated in the year 2006. Its today's share price is 351.2. Its current market capitalisation stands at Rs 11397.2 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2387.8 Cr and Total Income of Rs.2496.58 Cr. The company's management includes Kajal Damania, Robert J Spiegel, Ferzaan Engineer, Bhavna Doshi, T Rajamannar, Sudhir V Valia, Dilip S Shanghvi.

It is listed on the BSE with a BSE Code of 532872 , NSE with an NSE Symbol of SPARC and ISIN of INE232I01014. It's Registered office is at Plot No.5 & 6/1, Savli G. I. D. C. Estate,Savli - Vadodara Highway,Manjusar Vadodara-391775, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloitte Haskins & Sells LLP, Deloittee Haskins & Sells, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.